成人T细胞白血病-淋巴瘤患者接受莫格利珠单抗后CD8+ T细胞稳健增殖与多样化
本研究分析成人T细胞白血病-淋巴瘤(ATL)患者接受莫格利珠单抗前后外周血单个核细胞T细胞受体β链 repertoire,发现16例出现皮肤相关不良事件、8例无此类事件,另纳入11例化疗前后患者及24例免疫相关基因表达评估;莫格利珠单抗导致CCR4+ T细胞耗竭及淋巴细胞减少,引发稳态CD8+ T细胞增殖,皮肤相关不良事件患者增殖与多样化显著高于无事件者,增殖多样化细胞几乎均为新出现克隆。
要点
- 莫格利珠单抗治疗致CCR4+ T细胞耗竭和淋巴细胞减少,引发稳态CD8+ T细胞增殖。
- 皮肤相关不良事件患者CD8B和CD8A表达升高显著高于无事件患者。
- 增殖多样化的CD8+ T细胞几乎均为新出现克隆。
核心结论
- 莫格利珠单抗的淋巴细胞耗竭治疗引发稳态CD8+ T细胞增殖,主要为新出现克隆,部分克隆可能在莫格利珠单抗诱导的皮肤相关不良事件发病机制中起重要作用。
研究设计与样本
- 分析ATL患者接受莫格利珠单抗前后外周血单个核细胞T细胞受体β链 repertoire,皮肤相关不良事件16例、无事件8例;另纳入11例化疗前后无莫格利珠单抗患者;评估24例莫格利珠单抗前后免疫相关基因表达。
主要发现
- 莫格利珠单抗治疗导致CCR4+ T细胞耗竭,CD8B和CD8A表达升高在皮肤相关不良事件患者中显著高于无事件患者。
- 皮肤相关不良事件患者的T细胞多样化显著高于无事件患者。
- 莫格利珠单抗后增殖和多样化的CD8+ T细胞几乎完全为新出现克隆。
- CCR4+ T细胞耗竭程度与CD8+ T细胞增殖和多样化增加呈反向关系。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Skin-related adverse events (AEs) occur frequently in adult T-cell leukemia-lymphoma (ATL) patients treated with mogamulizumab, a humanized anti-CCR4 monoclonal antibody. This study was undertaken to elucidate the mechanisms of mogamulizumab-induced skin-related AEs. We analyzed the T-cell receptor β chain repertoire in ATL patients' peripheral blood mononuclear cells (PBMCs) before and after mogamulizumab. Skin-related AEs were present in 16 patients and were absent in 8 patients. Additionally, we included 11 patients before and after chemotherapy without mogamulizumab. Immune-related gene expression in PBMCs before and after mogamulizumab was also assessed (n = 24). Mogamulizumab treatment resulted in CCR4+ T-cell depletion, and the consequent lymphopenia provoked homeostatic CD8+ T-cell proliferation, as evidenced by increased expressions of CD8B and CD8A, which were significantly greater in patients with skin-related AEs than in those without them. We hypothesize that proliferation is driven by the engagement of self-antigens, including skin-related antigens, in the face of regulatory T-cell depletion. Together with the observed activated antigen presentation function, this resulted in T-cell diversification that was significantly greater in patients with skin-related AEs than in those without. We found that the CD8+ T cells that proliferated and diversified after mogamulizumab treatment were almost entirely newly emerged clones. There was an inverse relationship between the degree of CCR4+ T-cell depletion and increased CD8+ T-cell proliferation and diversification. Thus, lymphocyte-depleting mogamulizumab treatment provokes homeostatic CD8+ T-cell proliferation predominantly of newly emerging clones, some of which could have important roles in the pathogenesis of mogamulizumab-induced skin-related AEs.
引用
- Saito M, Ishii T, Urakawa I, et al. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma. Blood Adv. 2020. PMID: 32433748. doi:10.1182/bloodadvances.2020001641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。